This bundle combines CJC-1295 (a GHRH analogue) with Ipamorelin (a selective GHRP), the single most commonly discussed growth-hormone-axis research pairing on the premise that combining both pathways produces a larger combined effect than either alone.
This bundle combines two individually-researched compounds — CJC-1295 and Ipamorelin. See CJC-1295 and Ipamorelin for the full evidence behind each.
The stacking rationale has real, if indirect, pharmacological support. CJC-1295 is a GHRH analog; Ipamorelin is a ghrelin-receptor agonist (a GH secretagogue, or "GHRP") — the two act through independent receptor pathways. A 1990 human study found that combining a GHRH analog with a GH-releasing peptide (GHRP) at submaximal doses stimulated GH release synergistically — more than the sum of either given alone. Bowers et al., J Clin Endocrinol Metab, 1990
Important precision: this synergy was demonstrated for the GHRH+GHRP combination as a pharmacological class, using GHRH and GHRP-6 specifically — not the exact CJC-1295+Ipamorelin pairing sold here. No published trial has tested this specific pairing directly. The mechanistic logic for stacking is real; the specific product combination itself is unverified.
Needs the actual per-vial mg breakdown of CJC-1295 vs. Ipamorelin from tracked suppliers to calculate accurately.
They act on complementary growth-hormone-release pathways (GHRH and GHRP respectively), and combining them is the most common pairing discussed in this research area.
Yes, CJC-1295 and Ipamorelin each have their own dedicated page on this site with a full research overview and FAQ.
Yes, both compounds are prohibited under WADA S2.2 as growth-hormone-releasing substances.
It's the classic GHRH + GHRP pairing — CJC-1295 preps and refills the pituitary's GH stores, Ipamorelin triggers the release pulse, and because they hit different mechanisms, the combined effect is bigger than either alone.
Looking for something specific, or placing a wholesale order? Send us a DM or email.